Researchers looked back at medical records of 181 children with osteosarcoma, a type of bone cancer, who were treated with high-dose methotrexate. This chemotherapy drug needs to be cleared from the body within a specific timeframe, and delayed clearance can lead to complications. The study aimed to identify which patients might be at risk for this delay.
The team developed a computer prediction model using data from these patients. They found that 51 out of 181 patients experienced delayed methotrexate clearance. Their model, which used nine different patient factors, showed good accuracy in predicting this delay based on the data they had.
It's important to understand this was a retrospective study, meaning it analyzed information that was already collected. The model was created and tested on the same group of patients. No information was provided about side effects or safety concerns in this specific analysis.
While this research is a step toward better managing treatment, the prediction model has not yet been validated in a new, separate group of patients. Doctors cannot use this tool in practice yet. The findings suggest that with more research, such models might one day help identify children at risk earlier during their cancer therapy.